New Immune-Blocking drug tested in humans for first time
NCT ID NCT06797375
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested RLYB116, a small protein that blocks a part of the immune system called complement, in 16 healthy adults. The main goal was to see if it is safe and how the body handles it. Researchers also checked how well it stops complement activity. This is a first step toward possibly treating blood and autoimmune diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RLYB116 (a small protein that blocks part of the immune system called complement)
What this could lead to
If successful, this could lead to a new treatment for blood and autoimmune diseases by controlling harmful immune activity.
What could go wrong
This is a very early, small study in healthy people, not patients. It only checks safety and drug levels, not whether it works for any disease. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Brisbane
Brisbane, Queensland, 4006, Australia